Results 141 to 150 of about 61,476 (246)

MTAP Loss and Pleural Mesothelioma (PM): Current Treatment Strategies and Emerging Therapeutic Approaches. [PDF]

Cancers (Basel)
Cedres S, Masfarre L, Priano I, Valdivia A, Rocha P, Iranzo P, Pardo N, Martinez-Marti A, Arbusà A, Cane L, Soleda M, Sinigaglia B, Polo-Alonso S, Romero-Sola G, Caro-Consuegra R, Ortega A, Felip E.   +16 more
europepmc   +1 more source

Clinical Significance of a Cell‐Of‐Origin‐Based Classification in Pancreatic Ductal Adenocarcinoma

Cancer Science, EarlyView.
Schematic overview of a cell‐of‐origin‐based classification of pancreatic ductal adenocarcinoma (PDAC), highlighting distinct biological features and therapeutic implications of Acinar‐ and Ductal‐subtypes. ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with limited therapeutic options and poor clinical ...
Tatsuya Kikuchi, Soichiro Ako, Hironari Kato, Hideaki Kinugasa, Masaki Uchida, Takashi Oda, Ryosuke Hirai, Akihiro Matsumi, Kazuya Miyamoto, Hiroyuki Terasawa, Yuki Fujii, Daisuke Uchida, Kazuyuki Matsumoto, Koichiro Tsutsumi, Shigeru Horiguchi, Kazuya Yasui, Tomokazu Fuji, Kosei Takagi, Hirokazu Kato, Tomoyuki Honda, Fumio Otsuka, Motoyuki Otsuka   +21 more
wiley   +1 more source

Exploring the Melanoma and Pancreatic Cancer Phenotype of a Potential <i>CDKN2A</i> Founder Variant, I49T (c.146T>C; p.Ile49Thr), in Individuals of Predominantly Mexican Ancestry. [PDF]

JCO Precis Oncol
Hernandez D, Browning A, Gemmell A, Lara-Otero K, Niell-Swiller M, Mersch J, Mraz KA, Kamara D, Blanco A, Cardona Y, Chang E, Comeaux JG, Culver JO, Ford JM, Gutierrez N, Lester J, Karlan BY, Li M, Nie Q, Resendiz J, Wei ML, Ricker CN.   +21 more
europepmc   +1 more source

CDKN2A-mutation in a family with hereditary malignant melanoma.

, 2014
Malignant melanoma (MM) is a frequent form of cancer with increasing incidence. 6-10% of patients with MM report a family history of MM, and in most populations 2% of unselected cases of MM carry a CDKN2A mutation.
Lorentzen, Henrik, Djursby, Malene, Borg, Ake, Gerdes, Anne-Marie, Krogh, Lotte, Wadt, Karin   +5 more
core  

A 38‐year‐old female with seizures and a cortico–subcortical mass

Brain Pathology, EarlyView.
Marjolein Billen, Annemerel Van Wylick, Anne‐Marie Vanbinst, Hendrik Everaert, Freya Vaeyens, Johnny Duerinck, Bart Neyns, Stefanie Brock   +7 more
wiley   +1 more source

Comprehensive Genomic Profiling Beyond Driver Testing in Non‐Squamous Non‐Small Cell Lung Cancer With Known Drivers

Cancer Science, EarlyView.
Figure 6 Comprehensive genomic profiling identified additional actionable alterations in a substantial proportion of patients with non‐squamous NSCLC despite previously identified driver alterations, with some findings leading to subsequent matched targeted therapies.
Yoshihiro Masui, Tatsuya Yoshida, Yoh Yamaguchi, Jun Miyakoshi, Ryoko Inaba Higashiyama, Akiko Tateishi, Yuki Shinno, Yuji Matsumoto, Yusuke Okuma, Tomonori Mizutani, Hidehito Horinouchi, Kouya Shiraishi, Takashi Kohno, Takafumi Koyama, Noboru Yamamoto, Yasushi Goto   +15 more
wiley   +1 more source

Erratum: [Corrigendum] Fisetin ameliorates atherosclerosis by regulating PCSK9 and LOX-1 in apoE^-/- mice. [PDF]

Exp Ther Med
Yan L, Jia Q, Cao H, Chen C, Xing S, Huang Y, Shen D.   +6 more
europepmc   +1 more source

Dynamic Changes of ctDNA‐Based MRD and Genomic Mutations Predict Prognosis in ESCC Treated With Definitive Radiotherapy

Cancer Science, EarlyView.
In patients with esophageal squamous cell carcinoma receiving definitive radiotherapy combined with systemic therapy, posttreatment TP53 mutation clearance and ctDNA‐MRD negativity predict favorable outcomes, whereas persistent ctDNA signals indicate elevated relapse risk, supporting nucleosome‐ and MRD‐informed surveillance and risk‐stratification ...
Shutang Liu, Qi Wang, Chun Han, Xiaoning Li, Rutian Cheng, Lihong Liu, Hua Dong, Xuejiao Ren, Shuman Zhen, Lan Wang   +9 more
wiley   +1 more source

A Pathway to Chordoma Treatment: A Review on CDKN2A and Therapeutic Targeting. [PDF]

Cancers (Basel)
Mohiuddin M, Vaca B, Haynal E, Bin-Alamer O, Zaki P, Abou-Al-Shaar H, Zenonos GA, Perez HA, Lopez-Gonzalez M, Gersey ZC.   +9 more
europepmc   +1 more source

Japanese Society for Hereditary Tumors Guidance: Hereditary Cancer Syndromes With Multigene Panel Testing, 2025 Edition

Cancer Science, EarlyView.
Schematic of the clinical algorithm for diagnosing hereditary cancer syndromes using MGPT. ABSTRACT In March 2025, the Japanese Society for Hereditary Tumors and the Ministry of Health, Labour and Welfare (MHLW) Research on Promotion of Cancer Control Program Grant Number JPMH 23EA1037 published the “Japanese Society for Hereditary Tumors Guidance ...
Reiko Yoshida, Akira Hirasawa, Issei Imoto, Tatsuro Yamaguchi, Kensuke Kumamoto, Momoko Araki, Arisa Ueki, Kenta Masuda, Yusaku Urakawa, Noriko Tanabe, Atsushi Watanabe, Makoto Hirata, Tomoyuki Aruga, Takeshi Kuwata, Yoshinaga Okugawa, Keika Kaneko, Hiroko Terui‐Kohbata, Megumi Matsumoto, Sayaka Ueno, Katsutoshi Oda, Hisako Ono, Akihiro Sakurai, Hirotaka Matsui, Gou Yamamoto, Hideki Yamamoto, Yasuko Yamamoto, Masachika Ikegami, Yusuke Ohkuma, Kazuhiko Shien, Shigenobu Suzuki, Shunsaku Takayanagi, Masahiko Tanabe, Hisashi Hasumi, Naohito Hatta, Hiroyoshi Hattori, Hiroyuki Matsubayashi, Wataru Yamagami, Masayoshi Yamada, Kazuyuki Oishi, Tomomi Oka, Shinya Oda, Yusuke Kobayashi, Kazuhiro Takekoshi, Takeshi Nakajima, Yoshiko Nakano, Yoshiko Nakayama, Fumiharu Miura, Yasuyuki Miyakura, Yoshiko Mori, Akiyo Yoshimura, Masato Yonamine, Kunitoshi Shigeyasu, Hiroko Fujita, Mashu Futagawa, Kouji Ohta, Junko Kawano, Tomoharu Tokutomi, Ayaka Sato, Takeshi Makabe, Tomoko Yoshihama, Miki Aitani, Kaori Kimura, Nabue Takaiso, Chikako Tomozawa, Yumie Hiraoka, Manami Matsukawa, Hideyuki Ishida   +66 more
wiley   +1 more source